Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Up 6.0% Today

What is Tandem Diabetes Care, Inc.?

Tandem Diabetes Care (TNDM) is a leading insulin delivery and diabetes technology company based in San Diego, California. The company produces advanced automated insulin delivery systems like the Tandem Mobi and t:slim X2 insulin pumps. Today, TNDM saw a strong bullish movement in the market.

Why is Tandem Diabetes Care, Inc. going up?

TNDM stock is up 6.0% on Apr 30, 2026 15:36

• Tandem Diabetes Care disclosed upcoming conference appearances at two notable investor conferences, hinting at positive prospects and potentially exciting updates for investors.
• The FDA clearance for Tandem's Control-IQ+ automated insulin delivery technology for pregnancy in Type 1 Diabetes may have increased investor confidence in the company's innovative products and market potential.
• Vanguard Portfolio Management's substantial investment in Tandem Diabetes Care underscores investor interest and confidence in the company's future growth prospects.
• The overview of Tandem's market opportunity, dedication to innovation, and emphasis on commercial transformation likely contributed to the market's bullish trend as investors recognize the company's strong position in the global diabetes market.

TNDM Price Chart

TNDM Technical Analysis

TNDM News

Tandem Diabetes Care Announces Upcoming Conference Presentations

Tandem Diabetes Care, Inc. announced that its management will present company updates at two upcoming investor conferences: the BofA Securities 2026 Health Care Conference on May 12, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. Webcasts of these presentations will be available live and archived on the company's Investor Center website. Tandem Diabetes Care manufactures and sells advanced automated insulin delivery systems like the Tandem Mobi and t:slim X2 insulin pumps.

https://www.businesswire.com/news/home/20260429093228/en/Tandem-Diabetes-Care-Announces-Upcoming-Conference-Presentations

Tandem Diabetes Care Announces Upcoming Conference Presentations

Tandem Diabetes Care, Inc. announced that its management will present company updates at two upcoming investor conferences: the BofA Securities 2026 Health Care Conference on May 12, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. Both presentations will be webcast live, with archive recordings available for 30 days on the company's Investor Center website. Tandem Diabetes Care is a leading insulin delivery and diabetes technology company based in San Diego, California.

https://ca.finance.yahoo.com/news/tandem-diabetes-care-announces-upcoming-200500355.html

Vanguard Portfolio Management (TNDM) reports 4.05M shares, 5.91% stake

Vanguard Portfolio Management has reported a 5.91% stake in Tandem Diabetes Care Inc., holding 4,052,274 shares of Common Stock. This disclosure is made via a Schedule 13G filing, indicating a passive investment, and includes shares held for Vanguard funds and managed accounts. Ashley Grim, Head of Global Fund Administration, signed the filing.

https://www.stocktitan.net/sec-filings/TNDM/schedule-13g-tandem-diabetes-care-inc-passive-investment-disclosure-5-e0a363bd680e.html

Tandem Diabetes Care’s Control-IQ+ Automated Insulin Delivery Technology Now FDA Cleared for Pregnancy in Type 1 Diabetes

Tandem Diabetes Care announced that its Control-IQ+ automated insulin delivery (AID) technology has received FDA clearance for use in pregnancy complicated by type 1 diabetes mellitus. This makes Tandem's t:slim X2 and Tandem Mobi the first and only commercially available AID systems cleared for pregnancy in the U.S. The clearance is based on the CIRCUIT trial, which showed that the Control-IQ group experienced significantly more time in the pregnancy-specific glucose target range compared to standard therapy.

https://www.biospace.com/press-releases/tandem-diabetes-cares-control-iq-automated-insulin-delivery-technology-now-fda-cleared-for-pregnancy-in-type-1-diabetes

Tandem Diabetes Care (TNDM) Corporate presentation Summary

Tandem Diabetes Care (TNDM) presented a summary of its corporate strategy, highlighting its market opportunity in the underpenetrated global diabetes market with products like the t:slim X2 and Tandem Mobi. The company emphasizes its commitment to R&D, innovation with the Sigi platform in development, and its Control-IQ+ technology and Tandem Source digital ecosystem for comprehensive diabetes management. Recent events and filings also indicate a focus on commercial transformation, pharmacy channel shift, and continued growth.

https://quartr.com/events/tandem-diabetes-care-tndm-corporate-presentation_3Pa7WGp0

Trending Today

Natera, Inc. ($NTRA) Stock Forecast: Up 5.1% Today

First Solar Inc. ($FSLR) Stock Forecast: Up 5.2% Today

Cummins Inc. ($CMI) Stock Forecast: Up 5.1% Today

QUALCOMM Incorporated ($QCOM) Stock Forecast: Up 17.9% Today

C.H. Robinson Worldwide Inc. ($CHRW) Stock Forecast: Down 2.4% Today

AutoZone Inc. ($AZO) Stock Forecast: Up 5.1% Today

Kimco Realty Corporation ($KIM) Stock Forecast: Down 0.1% Today

Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Up 6.0% Today

Ambarella Inc. ($AMBA) Stock Forecast: Up 5.1% Today

Qorvo Inc. ($QRVO) Stock Forecast: Up 5.2% Today

Tandem Diabetes Care, Inc. Price History

21.03.2026 - TNDM Stock was down 5.2%

• Tandem Diabetes Care (TNDM) stock saw a decrease, despite TD Cowen boosting its price target to $28 and maintaining a Buy rating. The decline could be linked to investors taking profits after a period of price appreciation.
• The Chief Operating Officer of the company exercised restricted stock units (RSUs), with some shares held back for taxes. This action may have added selling pressure on the stock as more shares became available in the market.
• Although there was excitement surrounding the upcoming launch of the Mobi Tubeless product and a new pay-as-you-go program, these factors might not have been enough to counterbalance the short-term selling pressures that led to the observed decrease in stock value.

30.03.2026 - TNDM Stock was up 6.0%

• Tandem Diabetes Care disclosed upcoming conference appearances at two notable investor conferences, hinting at positive prospects and potentially exciting updates for investors.
• The FDA clearance for Tandem's Control-IQ+ automated insulin delivery technology for pregnancy in Type 1 Diabetes may have increased investor confidence in the company's innovative products and market potential.
• Vanguard Portfolio Management's substantial investment in Tandem Diabetes Care underscores investor interest and confidence in the company's future growth prospects.
• The overview of Tandem's market opportunity, dedication to innovation, and emphasis on commercial transformation likely contributed to the market's bullish trend as investors recognize the company's strong position in the global diabetes market.

28.03.2026 - TNDM Stock was down 6.6%

• The decrease in Tandem Diabetes Care's stock today may be due to profit-taking by investors following a period of positive momentum.
• Despite the favorable FDA clearance for the utilization of Control-IQ+ technology in pregnancy, the market's reaction might have been adverse as a result of already high expectations priced into the stock.
• The upgraded rating by Truist Securities and enthusiasm regarding the new pharmacy distributor model could have already been considered in the stock price, leading to a sell-off after the news.
• Investor concerns about the company's capacity to maintain growth and market presence in the competitive diabetes management sector may be contributing to a bearish outlook in the market.

28.03.2026 - TNDM Stock was down 5.5%

• The FDA clearance for Tandem Diabetes Care's Control-IQ+ automated insulin delivery technology for use in pregnancy complicated by type 1 diabetes, while positive news, might have raised concerns about potential competition in the market leading to a bearish sentiment.
• Despite positive analyst upgrades from Truist Securities and Piper Sandler on Tandem's new pharmacy distributor model and strategy, the market may have reacted negatively due to profit-taking by investors after recent gains.
• Tandem Diabetes Care's strategic transformation initiatives outlined at the TD Cowen 46th Annual Health Care Conference could be seen as promising for the company's future growth, but the market may have interpreted them as long-term investments impacting short-term profitability, contributing to the bearish movement.
• Overall, the bearish movement in TNDM stock today could be a result of a combination of profit-taking, market competition concerns, and short-term impact of strategic transformations on profitability.

30.02.2026 - TNDM Stock was down 5.4%

• An amended Schedule 13G/A filing by The Vanguard Group, indicating 0 shares beneficially owned, could have triggered uncertainty among investors.
• An ongoing investigation by the Portnoy Law Firm regarding potential securities fraud linked to malfunctions in Tandem's insulin pumps likely impacted the company's product reliability and financial transparency, resulting in a stock price decline.
• Despite exceeding Q4 earnings estimates, a neutral recommendation from Mizuho and a consensus "Hold" rating from analysts may have contributed to the subdued sentiment surrounding Tandem Diabetes Care, aligning with the bearish market movement.
• The combination of the investigation, neutral recommendations, and the lack of clear bullish sentiments likely intensified selling pressure on TNDM shares, leading to the observable significant bearish movement.

14.03.2026 - TNDM Stock was up 6.0%

• The surge in TNDM stock price could be attributed to the company being perceived as undervalued, with a GF Score of 74 indicating above-average potential for long-term returns.
• Maintaining a "Hold" rating and a target price of $22 might have provided investors with confidence in the current valuation of the stock.
• Positive sentiment from an AI analysis suggesting specific trading strategies and key support levels could have attracted more investors to TNDM.
• The overall bullish trend in the diabetes care market, with projected growth and technological advancements, might have positively impacted TNDM's stock price as it positions itself as a key player in the industry.

08.03.2026 - TNDM Stock was up 5.6%

• The bullish movement in Tandem Diabetes Care's stock today could be attributed to the company's request for shareholder approval for an increase in shares to its Long-Term Incentive Plan, signaling confidence in its future growth prospects.
• The projected growth in the Smart Insulin Management Devices Market, where Tandem Diabetes Care is a key player, could have also positively impacted investor sentiment and contributed to the stock's rise.
• Despite a reduction in stake by a notable financial institution, the overall market seems optimistic about Tandem Diabetes Care's performance, especially with the upcoming announcement of its first-quarter 2026 financial results, which investors are eagerly anticipating for insights into the company's trajectory.

13.03.2026 - TNDM Stock was up 5.5%

• TNDM stock started positively with a 5.69% gain, surpassing the S&P 500 performance.
• The optimistic outlook is supported by AI models suggesting favorable short-term sentiment and specific trading recommendations for large investors.
• In spite of a reduced price target by Goldman Sachs, TNDM stock remained strong, demonstrating robust confidence from investors in the company's potential for growth.
• Anticipated market expansion in diabetes care market by 2030, along with TNDM's innovative product range, likely influenced the market positively as investors foresee rising demand for diabetes care solutions.

27.02.2026 - TNDM Stock was down 6.9%

• Tandem Diabetes Care, Inc. experienced a bearish movement due to a significant 19.9% stock price drop following the disclosure of a malfunction in its insulin pumps.
• An investigation regarding potential securities fraud added further uncertainty and negative sentiment towards the company.
• The malfunction in the insulin pumps, which could lead to serious health complications for users, likely raised concerns among investors about the company's product safety and reliability.
• The market reacted strongly to the news, reflecting the importance of transparency and reliability in the healthcare technology sector.

07.03.2026 - TNDM Stock was up 6.2%

• Significant divestment of Tandem Diabetes Care shares by JPMorgan Chase & Co. initially raised investor concerns, but the market sentiment later turned positive.
• Despite Tandem Diabetes Care's ongoing lack of profitability, the stock witnessed a bullish trend leading up to the upcoming Q1 2026 financial results announcement.
• A mix of analyst opinions, resulting in a "Hold" consensus rating, and upgrades from some firms, likely influenced the positive investor sentiment as the company's potential was reassessed.
• Market enthusiasm and confidence in Tandem Diabetes Care's future performance, bolstered by beating earnings estimates for the quarter, drove the stock to a significant bullish movement.

07.03.2026 - TNDM Stock was down 5.8%

• The Smart Insulin Management Devices Market is projected to grow substantially by 2033, indicating a positive industry outlook. However, Tandem Diabetes Care's stock experienced a bearish trend.
• A reduction of 36.1% in Tandem Diabetes Care's stake by JPMorgan Chase & Co. could have contributed to the negative sentiment surrounding the stock.
• Despite beating earnings estimates, Tandem Diabetes Care remains unprofitable, leading to mixed analyst sentiment and a "Hold" consensus rating.
• The upcoming announcement of Tandem Diabetes Care's Q1 2026 results may have investors cautious, waiting for insights into the company's performance and future prospects before making investment decisions.

16.03.2026 - TNDM Stock was down 6.1%

• TNDM shares rose by 4.8% to $20.10, despite being undervalued, potentially prompting profit-taking by investors and contributing to the bearish trend.
• Mizuho Securities has maintained a "Hold" rating with a target price of $22, suggesting a neutral outlook that may not be driving significant positive momentum for the stock.
• Institutional trading strategies utilizing AI models could have resulted in selling pressure if recommended short positions were achieved.
• Anticipated growth in the diabetes care market until 2030 may have redirected investor attention towards other industry leaders, negatively impacting TNDM's stock performance in the short term.